{"id":"pola1","name":"DNA polymerase alpha (POLA1)","symbol":"POLA1","route":"/targets/pola1/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9173","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101868","uniprot":"https://www.uniprot.org/uniprotkb/P09884/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P09884","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1828","open-targets":"https://platform.opentargets.org/target/ENSG00000101868","civic":"https://civicdb.org/genes/5422/summary","oncokb":"https://www.oncokb.org/gene/POLA1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=POLA1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=POLA1","depmap":"https://depmap.org/portal/gene/POLA1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000101868-POLA1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/5422","omim":"https://www.omim.org/entry/312040"}],"products":[{"id":"cytarabine","name":"Cytarabine","status":"approved","modality":"Pyrimidine nucleoside analogue (antimetabolite)","route":"/drugs/cytarabine/"}],"trials":[{"id":"ielsg43","name":"MATRix/IELSG43","nct":"NCT02531841","phase":"3","status":"positive"},{"id":"nct03182244","name":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","nct":"NCT03182244","phase":"3","status":"completed"},{"id":"nct02521493","name":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","nct":"NCT02521493","phase":"3","status":"active"},{"id":"nct04778397","name":"Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated","nct":"NCT04778397","phase":"3"},{"id":"nct02883049","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","nct":"NCT02883049","phase":"3","status":"completed"},{"id":"triangle","name":"TRIANGLE","nct":"NCT02858258","phase":"3","status":"positive"},{"id":"nct03416179","name":"A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia","nct":"NCT03416179","phase":"3","status":"completed"},{"id":"nct00557193","name":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","nct":"NCT00557193","phase":"3","status":"completed"},{"id":"lyma","name":"LyMa","nct":"NCT00921414","phase":"3","status":"positive"},{"id":"nct04293562","name":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","nct":"NCT04293562","phase":"3","status":"recruiting"},{"id":"nct00703820","name":"Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia","nct":"NCT00703820","phase":"3","status":"completed"},{"id":"nct00003436","name":"Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia","nct":"NCT00003436","phase":"3","status":"completed"},{"id":"nct00002719","name":"Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia","nct":"NCT00002719","phase":"3","status":"completed"},{"id":"nct00002658","name":"Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia","nct":"NCT00002658","phase":"3"},{"id":"nct04229979","name":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","nct":"NCT04229979","phase":"3","status":"active"},{"id":"nct03150693","name":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","nct":"NCT03150693","phase":"3","status":"recruiting"},{"id":"nct01117441","name":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","nct":"NCT01117441","phase":"3","status":"completed"},{"id":"prima-cns","name":"PRIMA-CNS","nct":"NCT06830421","phase":"3","status":"active"},{"id":"nct07007312","name":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","nct":"NCT07007312","phase":"3","status":"recruiting"},{"id":"nct00136084","name":"Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia","nct":"NCT00136084","phase":"3","status":"completed"},{"id":"nct03206671","name":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","nct":"NCT03206671","phase":"3","status":"active"},{"id":"nct07255872","name":"A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia","nct":"NCT07255872","phase":"2/3","status":"recruiting"},{"id":"nct06788756","name":"L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Re","nct":"NCT06788756","phase":"2/3","status":"recruiting"},{"id":"nct02205762","name":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","nct":"NCT02205762","phase":"2/3","status":"active"},{"id":"nct01700946","name":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","nct":"NCT01700946","phase":"2","status":"completed"},{"id":"nct01890746","name":"A Safety and Efficacy Study of Eltrombopag in Subjects With AML","nct":"NCT01890746","phase":"2","status":"completed"},{"id":"bmt-ctn-0803","name":"BMT CTN 0803","nct":"NCT01141712","phase":"2","status":"positive"},{"id":"ielsg32","name":"IELSG32","nct":"NCT01011920","phase":"2","status":"positive"},{"id":"nct00057811","name":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","nct":"NCT00057811","phase":"2","status":"completed"},{"id":"nct03591510","name":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","nct":"NCT03591510","phase":"2","status":"active"},{"id":"nct07387926","name":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","nct":"NCT07387926","phase":"1/2","status":"recruiting"},{"id":"nct03793478","name":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","nct":"NCT03793478","phase":"1/2","status":"active"}],"pathways":[],"companies":[],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}